Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to Hold at Stifel Nicolaus

Posted by Brian Himes on Nov 1st, 2026

Stifel Nicolaus cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a buy rating to a hold rating in a research note issued to investors on Thursday, MarketBeat.com reports. Stifel Nicolaus currently has $225.00 price target on the biopharmaceutical company’s stock.

Several other research firms also recently commented on ALNY. Wells Fargo & Company decreased their target price on Alnylam Pharmaceuticals from $256.00 to $253.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 14th. JPMorgan Chase & Co. dropped their target price on Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating for the company in a report on Wednesday, September 30th. Zacks Research lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Finally, Jefferies Financial Group boosted their price objective on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a “hold” rating in a report on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $317.95.

Check Out Our Latest Research Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Stock Down 5.2%

Shares of ALNY opened at $165.00 on Thursday. Alnylam Pharmaceuticals has a 52 week low of $163.30 and a 52 week high of $479.79. The firm has a market cap of $22.08 billion, a P/E ratio of 8.57 and a beta of 0.28. The firm’s 50-day simple moving average is $236.49 and its 200 day simple moving average is $286.19. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating the consensus estimate of $1.66 by $14.60. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 246.94%. The business’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.90 EPS. On average, analysts forecast that Alnylam Pharmaceuticals will post 6.58 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the sale, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Chicago Partners Investment Group LLC boosted its stake in shares of Alnylam Pharmaceuticals by 124.7% during the third quarter. Chicago Partners Investment Group LLC now owns 2,186 shares of the biopharmaceutical company’s stock valued at $490,000 after purchasing an additional 1,213 shares in the last quarter. Rakuten Investment Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 13.0% during the third quarter. Rakuten Investment Management Inc. now owns 20,289 shares of the biopharmaceutical company’s stock worth $5,155,000 after purchasing an additional 2,328 shares during the last quarter. Provenance Wealth Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $527,000. GraniteShares Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 12.7% in the third quarter. GraniteShares Advisors LLC now owns 1,825 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 205 shares during the period. Finally, Traynor Capital Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 22.6% in the third quarter. Traynor Capital Management Inc. now owns 12,818 shares of the biopharmaceutical company’s stock valued at $3,163,000 after buying an additional 2,360 shares during the period. Institutional investors own 92.97% of the company’s stock.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

About Alnylam Pharmaceuticals

(Get Free Report)

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.